Prediscan Medtech

What Prediscan Medtech does

Prediscan Medtech Private Limited is an India-based, pre-commercial health-tech company founded in 2023 and headquartered at IIT Madras Research Park in Chennai. It is building a cloud-based SaaS platform that uses deep-learning convolutional neural networks to analyze retinal fundus images and screen for multiple non-communicable diseases (NCDs) — Heart Disease, Chronic Kidney Disease, Liver Disease, Diabetes, and Hypertension — from a single non-invasive eye scan, while also estimating over eight systemic biomarkers including blood pressure, HbA1c, LDL cholesterol, eGFR proxies, and AST/ALT correlates. The technology is built on a proprietary India-specific dataset curated under Ethics Committee approval from Dr. Mehta's Hospital, Chennai, intended to mitigate Western-cohort bias; a provisional patent (Application No: 202441041375) has been filed covering the core method.

Name

Prediscan Medtech

Legal name

Prediscan Medtech Private Limited

Website

https://prediscan.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Prediscan Medtech is a Chennai-based pre-commercial AI healthtech company building a cloud SaaS platform that uses deep-learning retinal fundus image analysis to non-invasively screen Indian healthcare providers' patients for Heart Disease, CKD, Liver Disease, Diabetes, and Hypertension from a single eye scan.

Ownership category

akta.pro rank

Product category

AI Healthcare Screening Software

NAICS

Software Publishers (5132), Software Publishers (513210)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

akta.pro secondary industries

SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), Medical Imaging AI (HDAAAEAH)

Keywords

• AI healthcare screening
• Retinal image analysis
• Non-communicable disease detection
• Oculomics diagnostics
• Medical imaging SaaS

Headquarters

HQ city

Chennai

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. SaaS Screening Platform (Planned): Prediscan is developing a cloud-based SaaS platform providing AI-driven disease screening as a service to healthcare providers. Revenue model appears to be B2B SaaS subscription or per-screen pricing, though specific commercial terms are not yet publicly disclosed as the platform is in pre-commercial MVP pilot stage.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Prediscan Medtech sells a cloud-based SaaS platform that uses deep learning (Convolutional Neural Networks) to analyze retinal fundus images and screen patients for multiple non-communicable diseases (NCDs), including Heart Disease, Chronic Kidney Disease, Liver Disease, Diabetes, and Hypertension. From a single non-invasive eye scan, the platform extracts over eight systemic health biomarkers and generates actionable multi-disease risk reports intended for use by healthcare providers across India.

Product overview

Prediscan offers a unified AI-powered disease screening platform centered on non-invasive retinal eye scans. The core product is a cloud-based SaaS platform that processes fundus images through deep learning algorithms to simultaneously screen for multiple NCDs (Heart Disease, CKD, Liver Disease, Diabetes, Hypertension) and extract 8+ biomarkers in a single scan. A web-based demo is available for demonstration purposes. The platform is designed to be device-agnostic and works with various existing fundus cameras. Currently in clinical development stage with investigational use status, not yet FDA-approved.

Differentiator

Problem solved

Functional benefit

Products and services

• Prediscan AI-Powered NCD Screening Platform Cloud-based SaaS platform that analyzes retinal fundus images using deep learning to screen for multiple non-communicable diseases (NCDs) including Heart Disease, Chronic Kidney Disease, Liver Disease, Diabetes, and Hypertension. Extracts over eight health biomarkers non-invasively from a single eye scan and generates actionable multi-disease risk reports for healthcare providers across India. Designed to be device-agnostic, working with various existing fundus cameras.
• Prediscan Demo Interactive web-based demonstration of the Prediscan AI-powered retinal screening platform, accessible via Streamlit, showcasing the scan-to-risk-report workflow for prospective healthcare provider customers in India.

Quantifiable outcome

• Initial PoC accuracy up to 79% for NCD risk detection
• +3 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

Six partnerships are on record, tiered core, supporting and minor.

• IIT Madras Incubation CellcoreStrategic or Co-development PartnerPrediscan is incubated at the IIT Madras Incubation Cell, which provides research infrastructure, mentorship, startup support, and institutional credibility. The company is physically located at IITM Research Park, Chennai, and presented its innovation to the Indian Education Minister during an HTIC visit.
• GIMS Startup, NoidacoreStrategic or Co-development PartnerPrediscan secured incubation at GIMS Startup, Noida (Government Institute of Medical Sciences startup ecosystem) in addition to IIT Madras, providing dual institutional backing.
• Dr. Mehta's Hospital, ChennaicoreStrategic or Co-development PartnerDr. Mehta's Hospital, Chennai provided Ethics Committee approval for Prediscan's Indian dataset collection initiative, enabling systematic collection of anonymized retinal fundus images linked to clinical correlates under stringent ethical protocols.
• NVIDIAsupportingTechnology or IntegrationPrediscan is a member of NVIDIA Inception, a program for cutting-edge AI and deep learning startups that provides access to NVIDIA's technology stack, GPU resources, technical expertise, and ecosystem visibility.
• TIIC (Tamil Nadu Industrial Investment Corporation) Accelerator ProgramsupportingStrategic or Co-development PartnerPrediscan was selected as a finalist in the TIIC Accelerator Program, a government-backed startup acceleration initiative providing mentorship, funding pathways, and network access within the Tamil Nadu startup ecosystem.
• BUILD 3.0 BootcampminorStrategic or Co-development PartnerPrediscan participated in the BUILD 3.0 Bootcamp, a startup development and mentorship program supporting early-stage ventures with business development resources.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• iHealthScreen: iHealthScreen develops AI-based retinal screening tools for AMD and DR with cardiovascular risk estimation. Comparable as an emerging AI-retinal player focused on systemic disease prediction, with overlapping biomarker ambitions to Prediscan.

Broad incumbents

• Google Health (Verily): Verily (Alphabet) has published and clinically validated oculomics research showing systemic biomarkers (e.g., cardiovascular, renal) derivable from retinal images. Comparable as a broad incumbent working on the same biomarker-from-retina thesis with deeper resources, though not a focused SaMD vendor.

Direct peers

• AEYE Health: AEYE Health produces FDA-cleared AI for retinal image screening (DR and broader ocular/systemic disease) deployable in primary care. Comparable to Prediscan on retinal-image AI, screening workflow, and point-of-care deployment.
• Toku Eyes: Toku Eyes (formerly Toku) extracts cardiovascular and metabolic risk biomarkers from retinal images. Closely aligned with Prediscan's oculomics approach of deriving systemic health biomarkers (e.g., cardiovascular, renal, metabolic) from a single fundus scan.
• Digital Diagnostics: Digital Diagnostics built IDx-DR, the first FDA-authorised autonomous AI diagnostic (retinal imaging for diabetic retinopathy). Highly comparable to Prediscan's regulatory-and-clinical pathway for AI-based retinal screening in primary care settings.
• Eyenuk: Eyenuk develops EyeArt, an FDA-cleared autonomous AI for diabetic retinopathy screening from retinal fundus images. Directly comparable to Prediscan as a retinal-AI screening SaaS targeting systemic disease risk from eye scans.

Regional players

• 365Screening: 365Screening (UK-based) provides AI-augmented DR and systemic disease screening as a managed service using fundus cameras. Comparable to Prediscan as a SaaS screening platform, but operating primarily in a different geography.
• Remidio: Remidio (Bengaluru) builds smart, AI-enabled fundus cameras and screening platforms deployed across India and emerging markets. Comparable as an Indian regional player combining retinal imaging devices with AI screening workflows aimed at NCD/DR detection.
• Forus Health: Forus Health (Bengaluru) manufactures retinal imaging devices (3nethra series) and runs large-scale DR screening programmes in India. Comparable as a regional player operating retinal-imaging + AI screening for systemic disease risk in Indian healthcare settings.

Others

• HealthEx: HealthEx is an Indian AI-health data platform enabling consented health-data exchange between patients and providers. Adjacent comparable as an ecosystem participant focused on Indian health data infrastructure relevant to AI-screening workflow integration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/prediscan

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prediscan Medtech